Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structures of human DPP7 reveal the molecular basis of specific inhibition and the architectural diversity of proline-specific peptidases.
Bezerra GA, Dobrovetsky E, Dong A, Seitova A, Crombett L, Shewchuk LM, Hassell AM, Sweitzer SM, Sweitzer TD, McDevitt PJ, Johanson KO, Kennedy-Wilson KM, Cossar D, Bochkarev A, Gruber K, Dhe-Paganon S. Bezerra GA, et al. Among authors: shewchuk lm. PLoS One. 2012;7(8):e43019. doi: 10.1371/journal.pone.0043019. Epub 2012 Aug 29. PLoS One. 2012. PMID: 22952628 Free PMC article.
Exploration of the P1 SAR of aldehyde cathepsin K inhibitors.
Catalano JG, Deaton DN, Furfine ES, Hassell AM, McFadyen RB, Miller AB, Miller LR, Shewchuk LM, Willard DH Jr, Wright LL. Catalano JG, et al. Among authors: shewchuk lm. Bioorg Med Chem Lett. 2004 Jan 5;14(1):275-8. doi: 10.1016/j.bmcl.2003.09.088. Bioorg Med Chem Lett. 2004. PMID: 14684342
Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).
Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heerding DA, Minthorn E, Mencken T, Atkins C, Liu Q, Rabindran S, Kumar R, Hong X, Goetz A, Stanley T, Taylor JD, Sigethy SD, Tomberlin GH, Hassell AM, Kahler KM, Shewchuk LM, Gampe RT. Axten JM, et al. Among authors: shewchuk lm. J Med Chem. 2012 Aug 23;55(16):7193-207. doi: 10.1021/jm300713s. Epub 2012 Aug 8. J Med Chem. 2012. PMID: 22827572
Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K).
Lawhorn BG, Philp J, Zhao Y, Louer C, Hammond M, Cheung M, Fries H, Graves AP, Shewchuk L, Wang L, Cottom JE, Qi H, Zhao H, Totoritis R, Zhang G, Schwartz B, Li H, Sweitzer S, Holt DA, Gatto GJ Jr, Kallander LS. Lawhorn BG, et al. J Med Chem. 2015 Sep 24;58(18):7431-48. doi: 10.1021/acs.jmedchem.5b00931. Epub 2015 Sep 10. J Med Chem. 2015. PMID: 26355916
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L. Wood ER, et al. Cancer Res. 2004 Sep 15;64(18):6652-9. doi: 10.1158/0008-5472.CAN-04-1168. Cancer Res. 2004. PMID: 15374980
Novel and potent cyclic cyanamide-based cathepsin K inhibitors.
Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Shewchuk LM, Tavares FX, Willard DH Jr, Wright LL. Deaton DN, et al. Among authors: shewchuk lm. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1815-9. doi: 10.1016/j.bmcl.2005.02.033. Bioorg Med Chem Lett. 2005. PMID: 15780613
58 results